Metabolic Dysfunction-associated Steatohepatitis

(asked on 10th November 2026) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure consistent access across England to any NICE-recommended pharmacological treatments for metabolic dysfunction-associated steatohepatitis.


Answered by
James Frith Portrait
James Frith
Parliamentary Under-Secretary (Department of Health and Social Care)
This question was answered on 18th November 2026

Further to the answer of 6 February in response to Question 106401, the National Institute for Health and Care Excellence (NICE) is evaluating resmetirom and semaglutide for treating metabolic dysfunction-associated steatohepatitis. No final guidance has yet been published, but NHS England has undertaken a system readiness assessment for both treatments, the findings of which have been submitted to NICE as part of the appraisal process.

This assessment recognises that there is strong clinical expertise within specialist liver services, but that wider readiness will depend on capacity and pathway planning, particularly for non-invasive diagnostic testing. Provision of diagnostics such as FibroScan, Enhanced Liver Fibrosis testing, Intelligent Liver Function Testing and use of FIB-4 scores currently vary across regions, and addressing this variation is a key focus of NHS preparation.

If NICE recommends these treatments, NHS England would implement them in line with national guidance and clinical prioritisation. Given the likely size of the eligible population and current diagnostic constraints, implementation may be phased and prioritised to ensure patient safety, equity of access and service sustainability. Initial prescribing and early treatment management would be led by specialist hepatology or gastroenterology services, supported by specialist nurses, with training supplied to primary care providers.

The Department and NHS England will continue to work to ensure that, if approved, these treatments are introduced in a way that is fair, affordable and protects the wider NHS, while ensuring that patients with the greatest clinical need benefit as quickly as possible.

Reticulating Splines